| |
|
 |
| CollPlant Produces Human Collagen
On a Commercial Scale Using Plant Cells | | "We are able to `teach` tobacco plant cells to produce human collagen through inserting five human genes into them," says CEO Yehiel Tal. CollPlant is targeting wound healing and orthopedics. | | read full article... |
|
|
 |
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
 |
 | Prolor Makes Drugs BioBetter
Targets $25 B Therapeutic Protein Market | | Avri Havron, a 30-year veteran of Israel`s biotech industry, helped develop beta-interferon and hGH. But the best could be yet to come as he stewards Prolor, the developer of a technology that dramatically increases drug longevity. | | read full article... |
|
|
|
|
|
| |
|
|
|
|
|
| |
|
 |
| Novamed Buying Up Diagnostics
With Backing from $3 Billion Riverside Group | | “I have been given a blank check to spend in order to expand our product platform,” says Novamed CEO Emil Katz, explaining the company’s bold new business strategy. “Our goal is to achieve overall sales of $50 million over the next five years by integrating synergistic diagnostics technologies into our product platform.” | | read full article... |
|
|
|
|
|
| |
|
 |
| Alnylam Looking for Israeli RNA`s
Following QBI Deal | | "RNA interference is an innovation that is becoming a game-changer in all of biomedical research. We would be interested in working and partnering with companies developing RNA technologies." Barry Greene, President and COO of Alnylam. The company is currently collaborating with Israel`s QBI.
| | read full article... |
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
| |
|
top of the page
|
|
